• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

    10/3/24 8:00:00 AM ET
    $FHTX
    $MRNA
    $OMGA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FHTX alert in real time by email

    CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio.

    (PRNewsfoto/Invaio Sciences)

    Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner Emeritus at McKinsey & Company, where he has advised companies in advanced industries for more than 30 years. Andonian's background in driving strategic transformations across diverse industries aligns perfectly with Invaio's mission to revolutionize agriculture by providing farmers with more natural crop protection.

    "We are thrilled to have André take on the role of Chairman. His deep understanding of global industries, strategic acumen, and passion for sustainable solutions make him the ideal leader to guide Invaio into its next phase of growth and innovation," said Ignacio Martinez, General Partner at Flagship Pioneering. "I would also like to thank Robert for his important contribution to Invaio over the last five years and look forward to our continued collaboration."

    In addition to his role at McKinsey, Andonian has also held influential positions in various industries, including serving on the boards of leading companies, foundations and educational institutions.

    "I am honored to take on the role of Chairman at Invaio Sciences," said Andonian. "The company's approach to agriculture, grounded in cutting-edge science and a deep respect for nature, is truly transformative. I look forward to working with the team to accelerate Invaio's impact on sustainable agriculture, ensuring a healthier and more productive future for farmers and consumers alike."

    As Chairman, Andonian will play a key role in guiding Invaio's strategic direction, fostering partnerships, and scaling its innovative solutions to meet the challenges of modern agriculture. His appointment reflects Invaio's continued dedication to building a leadership team with the expertise and vision to drive meaningful change in the global agricultural sector.

    About André Andonian 

    André Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering. He has over three decades of experience advising companies around the globe on a broad range of strategic, operational, and organizational topics, with a longstanding presence in the APAC region.  

    Andonian is Senior Partner Emeritus at McKinsey & Company, where he worked for 34 years, including as Senior Partner, Chairman of Japan, and Managing Partner of Korea. He also led Client Impact & Experience across Asia and was a member of McKinsey's leadership teams in Asia, Europe, and the United States, advising clients in the high-tech, industrial, automotive & assembly, aerospace, basic materials, biotech, and private equity sectors. He was a long-term member of the firm's global board and held extensive additional senior leadership roles in support of growth, people, and overall knowledge development.  Prior to joining McKinsey, Andonian worked at Masco Corporation in the US and at IBM in Austria, Spain, and the Middle East.  

    Andonian also serves as an Independent Director of the Board of ADI, Chair of the Board of Cognaize in the US, and NC Chair of AEM Holdings in Singapore. He is a member of the Advisory Board of the Sports & Health Sciences Department of the Technical University of Munich, chairs the Foundation for Armenian Science and Technology, and is a Special Advisor to the American Chamber of Commerce in Korea.  

    As a Fulbright Scholar, Andonian received an MBA at the Wharton School of the University of Pennsylvania, an MA and BA in Social & Economic Sciences as well as a BSc in Engineering, all with highest distinction, from institutions in his hometown of Vienna, Austria.  

    About Invaio

    Invaio Sciences, a Flagship Pioneering company, is a bioplatform company accelerating the leap to nature-positive agriculture. The company builds on advances in human health and digital innovation to develop biological technologies for crop health, enabling farmers to both improve yields and use more natural crop health solutions. Invaio is addressing consumer demands and unlocking radical benefits for farmers and the environment, leaving every acre better today and for generations to come. For more information, please visit www.invaio.com or follow Invaio on X (Twitter) or LinkedIn.

    About Flagship Pioneering

    Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invaio-sciences-appoints-andre-andonian-as-chairman-of-the-board-of-directors-302266751.html

    SOURCE Invaio Sciences

    Get the next $FHTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FHTX
    $MRNA
    $OMGA
    $SANA

    CompanyDatePrice TargetRatingAnalyst
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    Foghorn Therapeutics Inc.
    $FHTX
    1/30/2025$10.00Buy
    B. Riley Securities
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    Sana Biotechnology Inc.
    $SANA
    1/8/2025Hold → Buy
    TD Cowen
    More analyst ratings

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sana Biotechnology upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/18/25 7:56:06 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Sana Biotechnology with a new price target

      Jefferies initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $7.00

      3/14/25 7:41:20 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    SEC Filings

    See more
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      6/17/25 4:01:55 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sana Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/6/25 4:05:17 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Foghorn Therapeutics Inc.

      10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

      5/14/25 7:07:10 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

      SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking p

      6/9/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology to Present at June 2025 Investor Conferences

      SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 10, 2025. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availa

      5/28/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseas

      5/22/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Smith Ian F

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:40 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parshall B Lynne

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:16 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mendelsohn Michael

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:28:43 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care